These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246 [TBL] [Abstract][Full Text] [Related]
4. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949 [TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458 [TBL] [Abstract][Full Text] [Related]
6. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876 [TBL] [Abstract][Full Text] [Related]
7. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Schoonenboom NS; Mulder C; Van Kamp GJ; Mehta SP; Scheltens P; Blankenstein MA; Mehta PD Ann Neurol; 2005 Jul; 58(1):139-42. PubMed ID: 15984010 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Gelfanova V; Higgs RE; Dean RA; Holtzman DM; Farlow MR; Siemers ER; Boodhoo A; Qian YW; He X; Jin Z; Fisher DL; Cox KL; Hale JE Brief Funct Genomic Proteomic; 2007 Jun; 6(2):149-58. PubMed ID: 17584762 [TBL] [Abstract][Full Text] [Related]
13. Increased amyloid beta protein levels in children and adolescents with Down syndrome. Mehta PD; Capone G; Jewell A; Freedland RL J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850 [TBL] [Abstract][Full Text] [Related]
15. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050 [TBL] [Abstract][Full Text] [Related]
16. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111 [TBL] [Abstract][Full Text] [Related]
17. CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease. Mulder SD; Heijst JA; Mulder C; Martens F; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R Ann Clin Biochem; 2009 Nov; 46(Pt 6):477-83. PubMed ID: 19729499 [TBL] [Abstract][Full Text] [Related]
18. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. El Mouedden M; Vandermeeren M; Meert T; Mercken M J Neurosci Methods; 2005 Jun; 145(1-2):97-105. PubMed ID: 15922029 [TBL] [Abstract][Full Text] [Related]
19. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566 [TBL] [Abstract][Full Text] [Related]
20. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease. Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]